CASP6 and metabolic dysfunction-associated steatohepatitis: Zhao et al. [7] found that an AMPK activator inhibited hepatocyte apoptosis by blocking Caspase 6 activity, thereby preventing the progression from fatty liver to nonalcoholic steatohepatitis (NASH) and subsequent hepatocyte death.